Clinical Trial Update: Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a combination of docetaxel, oxaliplatin, capecitabine, bevacizumab, and trastuzumab in locally advanced or metastatic gastric cancer an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Gastro-oesophageal Junction
• Gastric Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)
• OXALIPLATIN (Oxaliplatin)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Metastatic Gastric Cancer, Adenocarcinoma of the Gastro-oesophageal Junction | Phase 2 | Status: UNKNOWN